RGEN Repligen Corporation

Repligen Corporation to Present at Upcoming Investor Conferences

Repligen Corporation to Present at Upcoming Investor Conferences

WALTHAM, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be presenting at two upcoming investor conferences.

  • William Blair’s 43rd Annual Growth Stock Conference being held in Chicago June 6-8. Tony J. Hunt, President and Chief Executive Officer, is scheduled to present a company overview on June 8, 2023 at 11:20 a.m. CT.
  • Jefferies’ Global Healthcare Conference being held in New York June 7-9. Jon K. Snodgres, Chief Financial Officer, is scheduled to present a company overview on June 8, 2023 at 1:30 p.m. ET.

A live webcast of the conference presentations will be accessible through Repligen’s  website at , and will be available for replay for a limited period of time following the event.

About Repligen Corporation

Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are inspiring advances in bioprocessing for the customers we serve; primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs) worldwide. Our focus areas are Filtration, Chromatography, Process Analytics, Fluid Management and Proteins. Our corporate headquarters are located in Waltham, Massachusetts, with additional administrative and manufacturing operations worldwide. The majority of our manufacturing sites are located within the U.S. (California, Massachusetts, New Hampshire, New Jersey and New York), and we also have sites in Estonia, France, Germany, Ireland, the Netherlands and Sweden. For more information about the company, including Repligen news releases, see our website at . Follow us on and .

Repligen Contact:

Sondra S. Newman

Global Head of Investor Relations

(781) 419-1881

 



EN
31/05/2023

Underlying

RGENRepligen Corporation

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Repligen Corporation

 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen Reports First Quarter 2025 Financial Results

Repligen Reports First Quarter 2025 Financial Results Revenue of $169 million, year-over-year increase of 10% as reported and 14% organic non-COVID growthOrders increased sequentially and high-teens year-over-year Adjusted operating income increased 72% year-over-year Reiterates 2025 full year organic revenue guidance of 9.5% - 13.5% WALTHAM, Mass., April 29, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2025, covering the three-month period en...

April 29, 2025 1 EN
 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen to Report First Quarter 2025 Financial Results

Repligen to Report First Quarter 2025 Financial Results Webcast and Conference Call to Be Held Tuesday, April 29, 2025, at 8:30 a.m. ET WALTHAM, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its first quarter 2025 financial results on Tuesday, April 29, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- month reporting period ended March 31, 2025. The conference call will be accessi...

April 15, 2025 1 EN
 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen Appoints Jacob Johnson As Vice President Investor Relations

Repligen Appoints Jacob Johnson As Vice President Investor Relations WALTHAM, Mass., April 08, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment of Jacob Johnson as Vice President, Investor Relations. In this role, Mr. Johnson will lead the investor relations team’s engagement with the investment community, reporting to the company’s Chief Financial Officer, Jason K. Garland. Most recently, Mr. Johnson served as Managing Director, Research Analyst at Stephens Inc., where he followed the life sciences tools and pharma services sector. Mr. Garlan...

April 8, 2025 1 EN
 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices

Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices Portfolio includes PAT devices for real-time process monitoring, control and analysis WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RGEN), a life sciences company focused on bioprocessing technology leadership, and . (Nasdaq: MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices’ desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on th...

March 4, 2025 1 EN
 PRESS RELEASE
Free
RGEN Repligen Corpor...

Repligen Reports Fourth Quarter and Full Year 2024 Financial Results

Repligen Reports Fourth Quarter and Full Year 2024 Financial Results Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11% and 8% respectivelyOrders outpaced revenue by 6% in the fourth quarter Provides full year 2025 guidance of 8% to 12% reported growth and 10% to 14% excluding COVID-related revenue WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth...

February 20, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch